Kymera revenue surges 466.4% to $65.0M on Gilead option, Sanofi milestone; cash runway extends into 2029

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 11, 2025 · ~1 min read

Key Changes

• high

  Collaboration revenue jumped to $65.0M, driven by Gilead's $45M option exercise for KT-200 and a $20M Sanofi milestone for first patient dosing of KT-485.

  MD&A: Collaboration Revenue verify on EDGAR →
• high

  Cash and marketable securities rose to $1,505M from $963.1M, extending the expected runway into 2029, beyond multiple clinical inflection points.

  MD&A: Cash Runway verify on EDGAR →
• high

  R&D expenses rose 52% to $119.5M, driven by a $23.5M increase in STAT6 program costs as KT-621 advanced into two Phase 2b trials (BROADEN2 and BREADTH).

  MD&A: R&D Expenses verify on EDGAR →